Business Context and Reporting Period
Company: Milestone Scientific Inc. (MLSS)
Filing Type: Form 8-K (Current Report)
Date of Report: April 20, 2026
Event: Entry into a Material Definitive Agreement for a Private Placement of securities.
Key Financial Metrics and Transaction Details
- Securities Issued: 7,962,963 Units (each consisting of one share of Common Stock and one Warrant).
- Purchase Price: $0.27 per Unit.
- Gross Proceeds: $2,150,000 total (comprised of $1,799,000 cash and $351,000 from the conversion of Convertible Bridge Notes).
- Warrant Terms: Exercise price of $0.3375 (125% of purchase price); exercisable for cash only prior to the third anniversary of closing.
- Additional Potential Proceeds: Up to $2,687,500 if all Warrants are fully exercised.
- Use of Proceeds: General working capital and payment of past due accounts payable.
- Transaction Costs: No placement agent fees, underwriting discounts, or commissions were paid.
Material Changes and Related Agreements
- Convertible Bridge Notes: The Company previously issued $800,000 in Convertible Bridge Notes to directors in April 2025. A portion ($351,000) was converted into Units in this Private Placement.
- Note Amendment: To facilitate the conversion, the conversion floor for the applicable portion of the notes was amended from $0.50 to $0.27 to match the Private Placement price. The unconverted portion retains the $0.50 floor but allows the $4,000,000 equity financing threshold to be met on a cumulative basis.
- Registration Rights: The Company agreed to file a registration statement within 45 days of closing to register the resale of the Common Stock and shares issuable upon Warrant exercise.
- Lock-Up Agreements: Certain directors, officers, and stockholders agreed to a 12-month restriction on transferring Company securities.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the net proceeds to address liquidity needs, specifically for working capital and settling past due accounts payable. The transaction was conducted without a placement agent to minimize costs.
Risks and Contingencies:
- Dilution: The issuance of 7,962,963 shares and associated warrants will result in immediate and potential future dilution to existing shareholders.
- Regulatory Compliance: The transaction relied on exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D; purchasers represented they are accredited investors.
- Future Obligations: The Company is obligated to file and maintain a registration statement for the resale of these securities.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-closing to assess dilution impact.
- Confirm the status of the remaining $449,000 of Convertible Bridge Notes and their current conversion terms.
- Review the Company's cash position and accounts payable status to gauge the urgency of the capital raise.
- Monitor the filing of the registration statement required within 45 days of April 20, 2026.
- Check for any subsequent filings regarding the exercise of warrants or additional equity financing.